BridgeBio Pharma Inc. Common Stock (BBIO)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a value investor: I want understandable, durable earnings purchased at a sensible price. BridgeBio is not that today. It sells medicines for genetic diseases, and the top line is moving: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $243.7M versus $110.6M in fiscal Q2 2025. In fiscal Q1 2026, revenue was $194.5M. For FY2025, revenue was $502.1M, up from $221.9M in FY2024 and just $9.3M in FY2023. That is remarkable commercial traction. But the bottom line remains deeply negative: fiscal Q2 2026 net loss was $155.9M, or $0.78 per diluted share; fiscal Q1 2026 net loss was $166.6M, or $0.84; FY2025 net loss was $732.9M, or $3.78. Trailing free cash flow is -$437.8M, a -3.5% FCF yield on the $12.4B market cap at the 2026-10-13 close of $63.30. FairStock's calculated P/E is -17.78, ROCE is -26.00%, Piotroski F-Score is 3/9, and Altman Z-Score is -2.65. Those are not signs of financial strength. The Lynch category is none because the company lost money in each of the last four years. A biotech can have valuable intellectual property and a real medical mission, but I cannot see a margin of safety in current earnings. The price may be discounting a successful future; my concern is that the present business still consumes cash and has no profits. I would need evidence of durable profitability, not just revenue growth, before calling this a value opportunity.

In plain English: BridgeBio makes medicines for rare genetic diseases, including a heart drug called Attruby. Sales are growing quickly, but the company still loses a lot of money and uses more cash than it brings in. At $63.30 a share, the price looks expensive compared with the company's current profits, because there are none.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer